What is Cellular Biomedicine Group Median PS Value?
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Cellular Biomedicine Group's Median PS Value or its related term are showing as below:
CBMG's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.69 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Cellular Biomedicine Group Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cellular Biomedicine Group's Median PS Value
For the Biotechnology subindustry, Cellular Biomedicine Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellular Biomedicine Group's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellular Biomedicine Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cellular Biomedicine Group's Price-to-Median-PS-Value falls into.
Cellular Biomedicine Group Median PS Value Calculation
10-Year Median PS Ratio is 0.
Cellular Biomedicine Group's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellular Biomedicine Group (NAS:CBMG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cellular Biomedicine Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
19.75
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellular Biomedicine Group Median PS Value Related Terms
Thank you for viewing the detailed overview of Cellular Biomedicine Group's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cellular Biomedicine Group (Cellular Biomedicine Group) Business Description
Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBMG has been successfully added to your 